{"filing":{"accession_number":"0001493152-26-033451","cik":"0001595353","ticker":"GLMD","company_name":"Galmed Pharmaceuticals Ltd.","form":"6-K","filing_date":"2026-07-16","report_date":null,"primary_document":"form6-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1595353/000149315226033451/form6-k.htm"},"events":[{"id":18288,"run_id":16436,"accession_number":"0001493152-26-033451","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Galmed announces a breakthrough development of a novel lipid nanoparticle (LNP) formulation of Aramchol in collaboration with Barcode Nanotech, targeting cardiac delivery. This is a material operational/strategic milestone—a significant advancement in the company's product pipeline and formulation technology that could open new therapeutic indications (cardiac fibrosis) and partnerships. While not a discrete M\u0026A transaction, earnings release, or executive change, it represents a material development in the company's core drug-development strategy and competitive positioning in cardiometabolic diseases.","company_name":"Galmed Pharmaceuticals Ltd.","ticker":"GLMD","filing_date":"2026-07-16","form":"6-K","submitted_at":null,"items":[{"id":17052,"accession_number":"0001493152-26-033451","item_number":"EX-99.1","item_title":"ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Galmed announces a breakthrough development of a novel lipid nanoparticle (LNP) formulation of Aramchol in collaboration with Barcode Nanotech, targeting cardiac delivery. This is a material operational/strategic milestone—a significant advancement in the company's product pipeline and formulation technology that could open new therapeutic indications (cardiac fibrosis) and partnerships. While not a discrete M\u0026A transaction, earnings release, or executive change, it represents a material development in the company's core drug-development strategy and competitive positioning in cardiometabolic diseases.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-16T11:44:37.642133+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":17052,"accession_number":"0001493152-26-033451","item_number":"EX-99.1","item_title":"ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Galmed announces a breakthrough development of a novel lipid nanoparticle (LNP) formulation of Aramchol in collaboration with Barcode Nanotech, targeting cardiac delivery. This is a material operational/strategic milestone—a significant advancement in the company's product pipeline and formulation technology that could open new therapeutic indications (cardiac fibrosis) and partnerships. While not a discrete M\u0026A transaction, earnings release, or executive change, it represents a material development in the company's core drug-development strategy and competitive positioning in cardiometabolic diseases.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-16T11:44:37.642133+00:00","company_name":"Galmed Pharmaceuticals Ltd.","ticker":"GLMD","filing_date":"2026-07-16"}]}